Spotlight on Dr. Giulietta Riboldi

Posted on by Phil Franchina

Spotlight on Dr. Giulietta Roboldi Giulietta Riboldi, PhD, a post-doctoral fellow at the Marlene and Paolo Fresco Institute for Parkinson’s...see more disease and Movement Disorders at NYU Langone Health, is the recipient of a 2018 APDA Post-Doctoral Fellowship for her work studying how mutations in a protein called glucocerebrosidase (GBA) mutations lead to the development Parkinson’s disease (PD).

Read More

Marijuana & PD

Posted on by Phil Franchina

Marijuana & PD While the medications that doctors prescribe for PD can be helpful, there remain gaps in what the...see more medications can treat. Some people with PD are eager to find alternative methods to help their symptoms and look into whether other therapies, such as medical marijuana, also known as medical cannabis, can be useful.

Read More

FDA Approves Inbrija™ (levodopa inhalation powder) Parkinson’s disease

Posted on by Phil Franchina

FDA Approves Inbrija™ (levodopa inhalation powder) December 22, 2018 Acorda Therapeutics announced the FDA approval of INBRIJA™ (levodopa inhalation powder)...see more for the treatment of OFF periods in people with Parkinson’s disease (PD) taking carbidopa/levodopa. INBRIJA™ is expected to be available by prescription in the first quarter of 2019, to be distributed through a network of specialty […]

Read More

FDA Approves Focused Ultrasound for Tremor-predominant Parkinson’s disease

Posted on by Phil Franchina

FDA approves focused ultrasound for tremor-predominant Parkinson’s disease December 19, 2018 Tremor-predominant Parkinson’s disease (PD) joins Essential tremor (ET)...see more as an FDA-approved indication for the use of Focused ultrasound. Focused ultrasound is a technology in which beams of ultrasound waves are focused on a designated target thereby concentrating enough energy to create a small lesion. […]

Read More